RxDoctor Payments Data

Bushra Alam, DO

Internal Medicine · Frankfort, ILNPI 1083134118

Payments from drug & device makers

$1,171in general payments, 2019–2025

Across 52 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$140
  • United Therapeutics Corporation$125
  • Johnson & Johnson$120
  • Sun Pharmaceutical Industries Inc.$99
  • Pfizer$75
  • Novo Nordisk$66
  • plus $547 from 20 others

What the payments were for

  • Food & beverage$1,07292%
  • Education$998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,171 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$18,446
Medicare patients
77
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$15,257
Atorvastatin Calcium102$763
Rosuvastatin Calcium21$594
Metoprolol Succinate23$508
Albuterol Sulfate HfaAlbuterol Sulfate12$497
Nifedipine ErNifedipine14$440
Losartan Potassium40$306
Levothyroxine Sodium20$282
Pantoprazole Sodium31$263
Amlodipine Besylate45$240
Gabapentin23$226
Fluticasone Propionate18$216
Metformin Hcl26$179
Lisinopril28$133
Pregabalin18$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$66$15,25716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Frankfort

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →